New pill targets 'undruggable' cancer mutation in advanced tumors
Disease control
Ongoing
This trial is testing an experimental pill called MRTX849 (adagrasib) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study aims to find safe doses, see how the drug works in the body, and measure if it shrinks tumors. It includes 7…
Phase: PHASE1, PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC